Projection Mapping Showcase of "YOASOBI / 'Idol’” Premiered Saturday, December 14!
20.1.2025 04:14:00 CET | Business Wire | Press release
~ Over 450,000 Visitors Have Experienced "TOKYO Night & Light" ~
The Tokyo Metropolitan Government has been hosting year-round projection mapping displays at the iconic Tokyo Metropolitan Government Building (No. 1 Building). These displays use light and sound to create vibrant and diverse works of art, transforming the landmark into a new tourism resource that illuminates Tokyo’s nightscape. The event began in February of 2024 and has been visited by approximately 450,000 people to date.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250107191600/en/
YOASOBI / 'Idol’ (Photo: Business Wire)
Recently, a new projection mapping work featuring YOASOBI's globally acclaimed song "Idol" premiered on Saturday, December 14. The opening day saw a large number of visitors from both Japan and abroad, creating an exciting atmosphere befitting such a popular attraction.
Feedback from attendees included comments such as, "I came to Japan as a tourist, and after seeing the weekday version, I wanted to see the weekend version as well, so I came back," "This is the most powerful projection mapping I've ever seen -- it was truly moving," and "YOASOBI's new content had a retro vibe, which I really enjoyed. I don’t think you’d see something like this very often overseas.”
Visitors can enjoy projection mapping videos created by renowned domestic and international creators, who have been highly praised at international competitions. This event is quickly evolving into one of Tokyo's must-visit tourist attractions. With its exceptional artistry, cutting-edge technology, and world-class content, this "new nighttime tourism hotspot that lights up Tokyo's nights" is one to watch.
Overview of the Work | YOASOBI / "Idol"
The song "Idol" by YOASOBI, which gained widespread attention as the theme song for an anime, is a masterpiece that blends rhythmic and vibrant elements with themes of uncertainty and inner conflict. The projection mapping display brings the emotional nuances of this song to life, offering an immersive visual and auditory experience.
Creator: Yukihiro Oka (Japan)
* Please visit our website for the screening schedule.
https://tokyoprojectionmappingproject.jp/en/
About the song
YOASOBI’s hit song "Idol" broke records by surpassing 800 million cumulative streaming plays in the shortest time ever. It topped several major global charts, including the U.S. Billboard Global Chart “Global Excl. U.S.,” Apple Music’s “Top 100: Global,” and YouTube Music Charts TOP 100 Songs Global, setting unprecedented milestones in J-POP history.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250107191600/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom